신테카바이오

226330KOSDAQ

57.1 / 100

Reference Date: 2026-09-08

Financial Score20.0 / 40

News Sentiment20.1 / 25

Momentum2.0 / 20

Disclosure15.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 15.2% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Synetica Bio is a biotech venture company established in 2009, specializing in AI-driven drug discovery platforms and genomics big data solutions. Its core services include DeepMatcher® hit screening, personalized neoantigen identification (NEO-ARS®), and genomic precision medicine (NGS-ARS®), with revenue generated through both platform services and in-house drug pipelines. The company leverages its supercomputing infrastructure and partnerships to maintain a competitive edge in the industry.

Number of Employees

49people

Average Salary

61.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

0.99Industry Average 1.204.0Point

In line with industry avg

ROE

-61.27Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

7.90Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20254.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲1367.3% (2-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲4.2% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -41.1% (declining, 3yr)

Detailed News Sentiment

9 totalPositive 8Neutral 0Negative 1Average Sentiment Score 80.6

Positive
신테카바이오, 20억 3자배정 증자 넘어 '30억+α' 조달 검토…일반...
신테카바이오의 대규모 자금 조달 계획 확대는 신약 개발 프로젝트의 진전을 시사하며 기업 성장 가능성을 높임.
Positive
신테카바이오, 30억원 이상 일반공모 유증 추진 "바이오 성과 공유"
신테카바이오의 일반공모 유증 확대는 신약 개발 성과 공유와 임상 단계 진입을 위한 자금 확보에 긍정적 영향을 미칠 것으로 보인다.
Positive
신테카바이오, 검진·정밀의료·동물백신 진출…경영정상화 병행
신테카바이오의 사업 다각화 전략 발표로 인해 성장 가능성과 수익 증대 기대가 높아져 긍정적 평가.

Detailed Momentum

52-week position1.0Point

Near 52w low (5%, downtrend)

Current 1,299Won52-week high 5,90052-week low 1,050

1-month return0.0Point

1m -15.15% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

16 totalPositive 6Neutral 10Negative 0

Neutral[기재정정]소액공모공시서류(지분증권)2026-09-04
Positive[기재정정]주요사항보고서(유상증자결정)2026-09-04
Positive[기재정정]주요사항보고서(유상증자결정)2026-09-03
Positive유상증자최종발행가액확정 (제3자배정-소액공모)2026-09-02
Neutral의결권대리행사권유참고서류2026-09-02